secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2026-08-03T10:46:50+00:00
Accession:  0001356576-26-000035
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q2 revenue up 32% to $219.1M; raises FY guidance; announces merger with Indivior
--------------------------------------------------------------------------------

- Total revenues $219.1M, +32% YoY; growth products revenue $175.7M, +52% YoY.
- Qelbree net sales $89.2M (+15% YoY); GOCOVRI $37.6M (+2%); ONAPGO $13.5M; ZURZUVAE collab rev $35.4M.
- Company raises full-year 2026 financial guidance.
- Agreed to merge with Indivior in all-stock merger of equals, creating diversified CNS company.
- ONAPGO second supplier regulatory submission on track for Q3 2026, potential FDA approval by mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000035/0001356576-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000035/supn-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001356576-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer